Abstract
The pathogenesis of acute liver injury has been plagued by biologists and physicians. We know little about its therapeutic mechanism. Therefore, this study explored the mechanism of bifendate and muaddil sapra in the treatment of acute liver injury. Firstly, co-expression and cluster analysis of disease-related genes were carried out, and the Go function and KEGG pathway of modules and related genes were identified. Secondly, pivot analysis of modules can identify key regulators. On the other hand, based on the acute liver injury induced by CCl4, we use the combined analysis of proteomics and transcriptome to find therapeutic targets and related mechanisms of drugs. A total of 21 dysfunction modules were obtained, which were significantly involved in immune system, hepatitis and other related functions and pathways. Transcriptome analysis showed 117 targets for bifendate treatment, while 119 for muaddil sapra. Through exploring the mechanism, we found that the two drugs could modulate the module genes. Moreover, bifendate regulate the dysfunction module through ncRNA (SNORD43 and RNU11). Muaddil sapra can mediate dysfunction modules not only by regulating ncRNA (PRIM2 and PIP5K1B), but also by regulating TF (STAT1 and IRF8), thus having a wider therapeutic potential. On the other hand, proteome analysis showed that bifendate mainly regulated Rac2, Fermt3 and Plg, while muaddil sapra mainly regulated Sqle and Stat1. In addition, muaddil sapra regulates less metabolic related proteins to make them more effective. Overall, this study not only provides basic theory for further study of the complex pathogenesis of acute liver injury, but also provides valuable reference for clinical use of bifendate and muaddil sapra in the treatment of acute liver injury.
Highlights
With the continuous improvement of living environment and medical level, therapies applied to acute liver injury have emerged in an endless stream
Based on the weighted gene co-expression network analysis (WGCNA), we observed that these genes exhibited a significant group co-expression phenomenon in acute liver injury samples
Biologists have done a lot of research on this and have summarized a large part of the results in the NCBI-Gene database
Summary
With the continuous improvement of living environment and medical level, therapies applied to acute liver injury have emerged in an endless stream Such methods as non-surgical treatment management[1,2,3] have greatly improved the survival rate of patients. Its ectopic expression in the liver cells exacerbates the acute hepatitis and liver injury induced by Con A so that it is identified as a potential treatment target for acute and chronic hepatitis[9]. These important results have provided valuable guidance for this research work and have greatly inspired our thinking. By investigating the molecular mechanisms of bifendate and muaddil sapra in the treatment of acute liver injury, we have further deepened our insights into its treatment mechanism and provided a valuable reference for clinical drug guidance
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
